FDA’s Woodcock weighs in on role of NIH in drug development
The FDA Center for Drug Evaluation and Research (CDER) director Janet Woodcock said Wednesday that while the NIH has been instrumental to drug discovery and development, she does not think the NIH or academics should be in the business of developing new pharmaceuticals.
The comments came as part of the first day of a two-day meeting at the National Academies of Sciences, Engineering and Medicine in Washington, DC, on the role of the NIH in drug development innovation and the impact on patient access.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.